Nicox - Q323 update confirms trajectory for NCX-470
At its Q323 update Nicox reiterated its guidance that it expects to report primary efficacy data for the Denali study in 2025. Denali is the company’s second Phase III study assessing lead candidate NCX-470, a nitric oxide (NO) donating bimatoprost, in the treatment of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension (OHTN). The next clinical catalyst is the initiation of the Phase IIIb Whistler trial in Q423, which aims to assess NCX-470’s dual mechanisms of action (NO-release and uveoscleral outflow). The results (anticipated near YE24) could help differentiate NCX-470 from competing glaucoma therapeutics. At 30 September gross cash was at €14.6m, which we expect to provide a cash runway into June 2024, while the company continues to seek partnerships for NCX-470. After rolling forward our estimates, we obtain an equity valuation of €119.4m, or €2.38 per basic share.Nicox is engaged in the ophthalmic market. Co. markets several ophthalmic products in the United States and Europe with a portfolio of therapies and diagnostic tools that can help people to enhance their sight. Co. has developed naproxcinod, the first member of the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, for the treatment of the signs and symptoms of osteoarthritis. Beyond naproxcinod, Co. has a pipeline containing multiple nitric oxide-donating NCEs, which are in clinical development with partners for the treatment of diseases, such as hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.